@skyestarfyre@captgouda24 Ofc grad school should not be like industry in every way - academia should select for those passionate for academia, if ppl want money they should get an industry job. But keeping wages near a line of unlivability selects for rich kids and leaves a lot of talent on the table.
@captgouda24 For a single person with no dependents, sure, it’s livable. Should someone with dependents not deserve to have a chance to go to grad school? What about someone with disabilities?
@captgouda24 Harvard slashed admissions of many programs in half while raising a record amount of money and growing their endowment $3.7B to $57B. The cuts in grad enrollment were so controversial that a dean who opposed the cuts was fired (Lichtman). All this before the strike
We have released a preprint “Targeting AAV vectors to the CNS via de novo engineered capsid-receptor interactions”.
We developed gene delivery vectors with known mechanisms of action & predictable tropisms by targeting AAVs to specific proteins.
https://t.co/ObDwFiOoCC
1⃣Developing a method is just the first step. ✔️
2⃣Helping others adopt it is the second step 👇
Thanks to @aleks_petelski, @edemmott and the entire @slavovLab team for this @NatureProtocols article!
https://t.co/5QyqcmgwIS
And its out! My/@Emmottlab first PI paper “Characterising proteolysis during SARS-CoV-2 identifies viral cleavage sites and cellular targets with therapeutic potential”.
https://t.co/98VYfhUuQm
This was a huge collaborative effort with 19 authors spanning 4 continents!
My awesome sister just released her book!
Uplifted tells the personal stories of how 21 Asian American entrepreneurs built their businesses, overcame their greatest challenges, and drew strength from their identities to uplift others.
https://t.co/dFGt4kbLuo
We've created an interactive website to visualize >100,000 experimental measurements of how mutations to #SARSCoV2 RBD affect binding by antibodies & sera: https://t.co/uP3IKvnDw0 Explore it to examine a wealth of information about the antigenic effects of viral mutations. (1/n)
Version 2 of https://t.co/MhFrA3TIoK is up! New data selection interface, now able to handle all 733,480+ SARS2 genomes from GISAID.
Please send us your feedback and help us to debug the site!
@winocm@Ayjchan@shingheizhan@CovidCg@DevermanLab We also have a version of the site that is run off of GenBank data instead of GISAID data (https://t.co/Ab2Z5TQ9JK). It has a few more features enabled, like per-sequence metadata/SNV downloads
We’ve updated our SARS-CoV-2 preprint investigating proteolysis by viral and host enzymes during SARS-CoV-2 infection! Lots of new data, and an author list now covering 4 countries on 3 continents! Read it here: https://t.co/OvefCifbxt
Our joint single-cell analysis of proteins & RNAs in differentiating macrophages appeared in @GenomeBiology https://t.co/8Agmu0HjiO (preprint: https://t.co/bbicPCZIeN)
We analyzed ~ 3,000 proteins and RNAs across single monocytes and macrophages, and found ...
New paper: Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity using SCoPE2. https://t.co/u5zF1B4oGV now published in @GenomeBiology
I’m delighted to share the first @emmottlab preprint! In this paper we study protease activity in #SARSCOV2 infected cells. We found multiple unknown cleavage sites in viral proteins, and novel cellular targets of the viral proteases essential for virus replication.
Our talk just got bumped earlier to 5 PM CDT / 6 PM EST. The closing talk for the @ASGCTherapy COVID-19 symposium. Grab your happy hour drink of choice and tune in for our 15-min talk! 🍻🍷🧋🍵🍼🧃🥤🍾🍸🥂🍹🧉🥛🧬 https://t.co/f1UH8laEiU
Heads up on a 2-day all-star @ASGCTherapy COVID-19 symposium starting tomorrow. Dr Fauci is the opening keynote. @atchen_@DevermanLab@shingheizhan our group is giving the last talk on Wednesday afternoon 5:15PM CDT! https://t.co/axpBoF10FI